论文部分内容阅读
目的观察阿昔洛韦对小儿EB病毒感染伴外周血白细胞总数降低病例的临床应用。方法对确诊小儿EB病毒感染的60例,外周血白细胞计数1.5～3.5×109/L患儿,使用阿昔洛韦治疗,10mg/(kg·d),分2次应用,疗程14d。根据临床症状和相关实验室检查判断疗效。结果经过治疗,30例EB病毒感染患儿给予阿昔洛韦治疗,显效19例,有效9例,无效2例,治疗两周后,治疗组白细胞总数升高、异型淋巴细胞数和EB病毒滴度下降比例均较对照组高,差异有统计学意义。结论阿昔洛韦治疗小儿EB病毒感染伴外周血白细胞总数降低病例,效果明显,无明显副作用,可在临床安全使用。
Objective To observe the clinical application of acyclovir in children with Epstein-Barr virus infection and reduce the total number of peripheral leukocytes. Methods 60 children with confirmed EB virus infection and 1.5 ~ 3.5 × 109 peripheral blood leukocyte counts were treated with acyclovir 10 mg / (kg · d) twice daily for 14 days. According to clinical symptoms and related laboratory tests to determine the efficacy. Results After treatment, 30 cases of children infected with Epstein-Barr virus were treated with acyclovir, 19 cases were markedly effective, 9 cases were effective and 2 cases were ineffective. After two weeks of treatment, the total number of leukocytes in the treatment group increased, the number of atypical lymphocytes and EBV Degree of decline than the control group were higher, the difference was statistically significant. Conclusion Aciclovir treatment of children with Epstein-Barr virus infection with a decrease in the total number of peripheral white blood cells, the effect is obvious, no significant side effects, can be safely used in clinical.